A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether combined surgical procedures in one or two stages are the best surgical treatment strategy in patients with simultaneous coronary artery disease and lung cancer. Altogether, 264 papers were found using the reported search; of which, 15 represented the best evidence to answer the clinical question. The authors, journal, date, country of publication, patient group, study type, outcomes and results of papers are tabulated. The outcomes of the reported studies provided interesting results. All the studies were retrospective. Ten papers reported the results of combined and staged operations. The operative mortality rate of combined procedures was 0-20.8% and of staged procedures was 0-10%. The reoperation rate for bleeding of combined procedures was 0-11% and of staged procedures was 0%. The survival rate of combined procedures at 1 year was 79-100%, at 5 years was 34.9-85% and at 7 years was 61%. The survival rate of staged procedures at 1 year was 72.7% and at 5 years was 53%. Five studies reported the results of off-pump coronary artery bypass grafting (OPCABG) and lung surgery versus on-pump and lung surgery. The operative mortality rate of OPCABG and lung surgery was 0-6.6%. The 2-year survival rate of OPCABG and lung surgery was 47% and the 5-year survival rate was 13-68%. The re-exploration rate for bleeding of OPCABG was 4%. Simultaneous lung surgery and CABG could be safely performed with adequate cancer-free survival in patients with Stage I or II lung cancer. Lung surgery is better performed before institution of cardiopulmonary bypass, avoiding the complications of such a technique. Long-term survival after combined treatment is mostly related to the predicted survival after lung resection. This depends on the T stage and mostly on the patient's nodal status. In certain high-risk groups (if the cardiac procedure is difficult or if the patient is unstable), separate staged procedures (CABG as the first and lung resection as the second procedure) might be the most prudent action (3-6 weeks apart). There is also another option: OPCABG and lung resection, which could be a safe and effective treatment when unstable coronary heart disease and lung cancer coexist.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] .
THREE-PART QUESTION
In [patients with simultaneous coronary artery disease and lung cancer] are [the combined surgical procedures in one or two stages] the best surgical treatment strategy to optimize [event-free survival]?
CLINICAL SCENARIO
A patient presents with coronary artery disease and a coronary artery bypass grafting (CABG) surgery is scheduled. During his preoperative work-up with a chest X-ray, an asymptomatic pulmonary lesion is found. A CT biopsy and PET scan finds this to be a T2aN0M0 adenocarcinoma. You wonder whether you should perform the CABG and then the lobectomy or attempt the two operations at the same time. In all staged procedures, cardiac surgery was done first and lung surgery was performed later
SEARCH STRATEGY
The mean interval between staged procedures was 33.9 ± 34.7 days (12-120 days)
In all concomitant procedures, except one, heart operations on CPB were followed by lung resection, either still on CPB (13 patients) or afterwards (11 patients) after reversing hypocoagulation, whereas in 10 patients, after closing the sternotomy, a posterolateral incision for the lung resection was performed 
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BEST EVIDENCE TOPIC
Miller et al. found that overall 1-and 5-year survival rates for the combined group were 79.7 and 34.9% and for the staged group were 72.7 and 53%, respectively. The 5-year survival rate for Stage I patients in the staged group was 100% and only 36.5% in the combined group.
Brutel de la Riviere et al. found that in combined procedures 2-and 5-year survival rates were 62 and 42%, respectively.
Rao et al. showed that, in combined lung surgery and cardiac operation, overall actuarial survival rates at 1, 5 and 7 years were 85 ± 7, 85 ± 7 and 61 ± 21%, respectively. Of the total, 63% of patients underwent pulmonary resection during CPB, which did not have a detrimental effect on 5-year survival. The operative death rate was 6.6% and the reoperation rate for bleeding was 3.3%.
Voets et al. found that the operative mortality rate was 20.8% in the concomitant group versus 10% in the staged group (but not statistically significant).
Danton et al. showed that there was no hospital mortality in performing simultaneous pulmonary resection and cardiac surgery. The overall survival rate was 61.5%. The survival rate of patients with bronchogenic carcinoma was 50%. Patane et al. found that the perioperative mortality rate was 0% in patients treated with simultaneous lung surgery and cardiac surgery. The survival rate during follow-up was 73%.
Ciriaco et al. demonstrated that the overall morbidity and mortality rates were 28 and 4%, respectively. There were no deaths among patients who had prior CABG.
Saxena and Tam showed that the hospital mortality rate was 0% and the late death rate was 33.3% in patients who were operated with combined off-pump CABG (OPCABG) and pulmonary resection. No recurrence for angina or malignancy was detected during follow-up.
Schoenmakers et al. found that the hospital mortality rate was 7% in the on-pump versus 6.6% in the off-pump group. The mean survival was 5.25 years in the on-pump versus 3 years in the off-pump group. The 2-year survival rate was 64% in the on-pump versus 47% in the off-pump group, and the 5-year survival rate was 46% in the on-pump versus 13% in the off-pump group, respectively.
Prokakis et al. found that the hospital mortality rate was 0% in patients who underwent combined lung and heart surgery. The survival rate was 100%.
Dyszkiewicz et al. showed that the perioperative death rate and perioperative myocardial infarction (MI) rate were 0% in combined OPCABG and lung cancer surgery. The death rate was 32% during follow-up, mostly because of cancer relapse. No patient had an MI during follow-up.
Cathenis et al. found that the in-hospital mortality rate was 0% in patients who were operated simultaneously for cardiac disease and pulmonary lesions. The median survival was 46 months for these patients.
Hosoba et al. found that there was no operative or hospital death in patients treated simultaneously with cardiac surgery and pulmonary resection. The operated patients had an 80% chance of 2-year survival.
Ma et al. found that the perioperative death rate and the new MI rate were 0% in combined OPCABG and lung cancer surgery. The survival rate during follow-up was 82%.
Zhang et al. showed that the 5-year survival rate was only 43.6% in patients with simultaneous cardiac and lung surgery for malignant pulmonary nodules versus 85.6% in patients with benign pulmonary nodules.
CLINICAL BOTTOM LINE
Ten papers reported the results of combined and staged operations. The operative mortality rate of combined procedures was 0-20.8% and of staged procedures was 0-10%. The reoperation rate for bleeding of combined procedures was 0-11% and of staged procedures was 0%. The survival rate of combined procedures at 1 year was 79.-100%, at 5 years was 34.9-85% and at 7 years was 61%. The survival rate of staged procedures at 1 year was 72.7% and at 5 years was 53%. Five studies reported the results of OPCABG and lung surgery versus on-pump and lung surgery. The operative mortality rate of OPCABG and lung surgery was 0-6.6%. The 2-year survival rate of OPCABG and lung surgery was 47% and the 5-year survival rate was 13-68%. The re-exploration rate for bleeding of OPCABG was 4%. Simultaneous lung surgery and CABG could be safely performed with adequate cancer-free survival in patients with Stage I or II lung cancer. Lung surgery is better performed before CPB, avoiding the complications of the latter Long-term survival after combined treatment is mostly related to the predicted survival after lung resection. This depends on T stage and mostly on the patient's nodal status. In certain high-risk groups (if the cardiac procedure is difficult or if the patient is unstable), separate staged procedures (CABG as a first and lung resection as a second operation) might be the most prudent action (3-6 weeks apart). There is also another option (OPCABG and lung resection), which is a safe and effective treatment when unstable coronary heart disease and lung cancer coexist.
